奈达铂联合多西他赛并同期放疗治疗不可手术食管癌的临床效果观察

目的探究不同化疗方案联合同期放疗治疗不可手术食管癌的临床效果及安全性,并为该病的临床治疗积累经验。方法选取本院肿瘤科2011年4月-2013年9月收治的62例食管癌中晚期患者,采用随机数字表法进行分组,分别设为研究组和对照组,每组31例。对照组采用氟尿嘧啶＋顺铂联合同期放疗,研究组采取奈达铂＋多西他赛联合同期放疗。记录并比较两组1年有效率、1年局控率、1年生存率及毒副反应发生率。结果研究组1年有效率为58.1%,高于对照组的32.2%,差异有统计学意义（P〈0.05）;两组1年局控率比较差异无统计学意义（P〉0.05）。研究组反射性食管炎发生率低于对照组,恶心呕吐及骨髓抑制发生率高于对照组,差异有统计学意义（P〈0.05）。研究组1年生存率为61.3%,对照组1年生存率为45.2%,差异无统计学意义（χ^2=1.265,P〉0.05）。结论奈达铂联合多西他赛同期放疗比顺铂联合氟尿嘧啶同期放疗治疗不可手术食管癌的效果更佳,毒副反应更轻且可控,患者治疗耐受性更好。

Clinical effect observation of nedaplatin combined with docetaxel and concurrent radiotherapy in the treatment for no-operation of esophageal cancer

Objective To explore the clinical effect and safety of different chemotherapy combined with concurrent radiotherapy in the treatment for no-operation of esophageal cancer,and accumulate experience for the clinical treatment of the disease. Methods 62 patients with esophageal carcinoma in our hospital from April 2011 to September 2013 were selected and divided into study group and control group,each group of 31 cases.The fluorouracil ＋DDP combined with concurrent radiotherapy were used in control group,while nedaplatin＋docetaxel combined with concurrent radiotherapy were applied in study group.The 1 year effective rate,1 year local control rate,1 year survival rate and incidence rate of chemotherapy toxicity in two groups were recorded and compared. Results 1 year effective rate in study group was58.1%,higher than that in control group（32.2%）,with statistical difference（P〈0.05）.1 year local control rate in two groups was compared,with no statistical difference（P〉0.05）.Incidence rate of reflective esophagitis in study group was lower than that in control group,incidence rate of nausea,vomiting and bone marrow suppression in study group was higher than that in control group respectively（P〈0.05）.1 year survival rate in study group was 61.3%,1 year survival rate in control group was 45.2%,with no statistical difference（χ^2=1.265,P〈0.05）. Conclusion Nedaplatin combined with docetaxel and concurrent radiotherapy in the treatment for no-operation of esophageal cancer can get a better curative effect than luorouracil combined with DDP and concurrent radiotherapy.Its side reaction is more light and controllable,tolerance of patient is better.